Orexo believes that the potential market share losses stemming from changes in Zubsolv’s status at CVS should be more than offset by a new exclusive managed Medicaid agreement. Orexo estimates 10-15% of Zubsolv gross sales could be affected by the CVS change, with Zubsolv remaining available to many, but not all CVS members. Although the CVS decision is disappointing, we are encouraged by recent prescription data, with Zubsolv’s market share now 6.3%, in addition to the new agreem
10 Aug 2015
Zubsolv CVS loss countered by a new agreement
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Zubsolv CVS loss countered by a new agreement
Orexo believes that the potential market share losses stemming from changes in Zubsolv’s status at CVS should be more than offset by a new exclusive managed Medicaid agreement. Orexo estimates 10-15% of Zubsolv gross sales could be affected by the CVS change, with Zubsolv remaining available to many, but not all CVS members. Although the CVS decision is disappointing, we are encouraged by recent prescription data, with Zubsolv’s market share now 6.3%, in addition to the new agreem